Literature DB >> 4058074

Complete remissions in non small cell lung cancer.

J Klastersky, J P Sculier, P Mommen.   

Abstract

We studied 241 patients with non small cell bronchogenic cancer who were treated with cisplatin and etoposide or cisplatin, etoposide and vindesine. There were 11 (4.5%) complete responders in these series most of whom had a prolonged survival.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4058074     DOI： 10.1007/BF02934775

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN： 0736-0118


  4 in total

1.  Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party.

Authors:  J Klastersky; J P Sculier; C Nicaise; D Weerts; M Mairesse; P Libert; P Rocmans; J Michel; W Ferremans
Journal:  Cancer Treat Rep       Date:  1983 Jul-Aug

2.  Commentary: current status of chemotherapy for non-small cell lung cancer.

Authors:  J Aisner; H H Hansen
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

3.  Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

Authors:  R J Gralla; E S Casper; D P Kelsen; D W Braun; M E Dukeman; N Martini; C W Young; R B Golbey
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

4.  Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium).

Authors:  E Longeval; J Klastersky
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.